AU2020251023B2 - Modulators of intracellular chloride concentration - Google Patents

Modulators of intracellular chloride concentration

Info

Publication number
AU2020251023B2
AU2020251023B2 AU2020251023A AU2020251023A AU2020251023B2 AU 2020251023 B2 AU2020251023 B2 AU 2020251023B2 AU 2020251023 A AU2020251023 A AU 2020251023A AU 2020251023 A AU2020251023 A AU 2020251023A AU 2020251023 B2 AU2020251023 B2 AU 2020251023B2
Authority
AU
Australia
Prior art keywords
benzoic acid
dimethylsulfamoyl
mmol
compound
trifluorooctylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020251023A
Other languages
English (en)
Other versions
AU2020251023A1 (en
Inventor
Marco BORGOGNO
Laura CANCEDDA
Andrea CONTESTABILE
Marco DE VIVO
Jose Antonio ORTEGA MARTINEZ
Annalisa SAVARDI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universita di Bologna
Fondazione Telethon
DIMES Dipartimento di Medicina Sperimentale Universita degli Studi di Genova
Fondazione Istituto Italiano di Tecnologia
Original Assignee
Universita di Bologna
Fondazione Telethon
DIMES Dipartimento di Medicina Sperimentale Universita degli Studi di Genova
Fondazione Istituto Italiano di Tecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universita di Bologna, Fondazione Telethon, DIMES Dipartimento di Medicina Sperimentale Universita degli Studi di Genova, Fondazione Istituto Italiano di Tecnologia filed Critical Universita di Bologna
Publication of AU2020251023A1 publication Critical patent/AU2020251023A1/en
Application granted granted Critical
Publication of AU2020251023B2 publication Critical patent/AU2020251023B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/43—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2020251023A 2019-04-02 2020-04-02 Modulators of intracellular chloride concentration Active AU2020251023B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT201900004929 2019-04-02
IT102019000004929 2019-04-02
PCT/IB2020/053158 WO2020202072A1 (en) 2019-04-02 2020-04-02 Modulators of intracellular chloride concentration

Publications (2)

Publication Number Publication Date
AU2020251023A1 AU2020251023A1 (en) 2021-11-04
AU2020251023B2 true AU2020251023B2 (en) 2025-11-27

Family

ID=67185615

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020251023A Active AU2020251023B2 (en) 2019-04-02 2020-04-02 Modulators of intracellular chloride concentration

Country Status (10)

Country Link
US (1) US20220184008A1 (https=)
EP (1) EP3947345A1 (https=)
JP (1) JP7676317B2 (https=)
KR (1) KR20220022051A (https=)
CN (2) CN114174259A (https=)
AU (1) AU2020251023B2 (https=)
CA (1) CA3135339A1 (https=)
IL (1) IL286900B2 (https=)
SG (1) SG11202110950XA (https=)
WO (1) WO2020202072A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202300007521A1 (it) * 2023-04-18 2024-10-18 Iama Therapeutics S R L Processo per la preparazione di derivati dell'acido sulfamoilbenzoico
WO2025257786A1 (en) * 2024-06-13 2025-12-18 Iama Therapeutics S.R.L. Benzoimidazole derivatives as nkcc1 inhibitors

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2517183A1 (de) * 1975-04-18 1976-10-28 Hoechst Ag Basisch substituierte 5-sulfamoyl- anthranilsaeurederivate und verfahren zu ihrer herstellung
US4029787A (en) * 1974-09-06 1977-06-14 Hoechst Aktiengesellschaft Basically substituted 3-sulfamoylbenzoic acid derivatives and process for their preparation
WO2000042004A1 (fr) * 1999-01-15 2000-07-20 Universite De Liege Derives de sulfonamides benzeniques et leurs utilisations
WO2000058277A1 (en) * 1999-03-31 2000-10-05 American Home Products Corporation Aryl sulfonic acids and derivatives as fsh antagonists
WO2001062718A1 (en) * 2000-02-25 2001-08-30 Japan Tobacco, Inc. Benzamide derivative and use thereof
WO2007058960A1 (en) * 2005-11-10 2007-05-24 Adolor Corporation Sulfamoyl benzamides as cannabinoid receptor modulators
WO2008052190A2 (en) * 2006-10-26 2008-05-02 Flynn Gary A Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3493584A (en) * 1966-02-21 1970-02-03 Smithkline Corp 4-substituted amino-5-sulfamoylbenzoic acid derivatives and preparation
DE2412884A1 (de) * 1974-03-18 1975-10-16 Hoechst Ag Basisch substituierte benzolsulfonamide und verfahren zu ihrer herstellung
DE3101960A1 (de) * 1981-01-22 1982-09-02 Hoechst Ag, 6000 Frankfurt "basisch substituierte anthranilsaeuren, verfahren zu ihrer herstellung und ihre verwendung"
US6355633B1 (en) * 1999-03-31 2002-03-12 American Home Products Corporation Aryl sulfonic acids and derivatives as FSH antagonists
JP2002201172A (ja) * 2000-02-25 2002-07-16 Japan Tobacco Inc ベンズアミド誘導体及びその用途
NZ573875A (en) * 2006-06-22 2011-11-25 Anadys Pharmaceuticals Inc Pyrro[1,2-b]pyridazinone compounds
EP2389371A4 (en) * 2009-01-22 2012-09-12 Neurotherapeutics Pharma Inc ANALOGUES OF BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE AND TORSEMID, AND RELATED COMPOSITIONS AND METHODS OF USE
JP2011231094A (ja) * 2009-11-02 2011-11-17 Neurotherapeutics Pharma Inc ブメタニド、フロセミド、ピレタニド、アゾセミド、およびトルセミドのアナログ、組成物および使用方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029787A (en) * 1974-09-06 1977-06-14 Hoechst Aktiengesellschaft Basically substituted 3-sulfamoylbenzoic acid derivatives and process for their preparation
DE2517183A1 (de) * 1975-04-18 1976-10-28 Hoechst Ag Basisch substituierte 5-sulfamoyl- anthranilsaeurederivate und verfahren zu ihrer herstellung
WO2000042004A1 (fr) * 1999-01-15 2000-07-20 Universite De Liege Derives de sulfonamides benzeniques et leurs utilisations
WO2000058277A1 (en) * 1999-03-31 2000-10-05 American Home Products Corporation Aryl sulfonic acids and derivatives as fsh antagonists
WO2001062718A1 (en) * 2000-02-25 2001-08-30 Japan Tobacco, Inc. Benzamide derivative and use thereof
WO2007058960A1 (en) * 2005-11-10 2007-05-24 Adolor Corporation Sulfamoyl benzamides as cannabinoid receptor modulators
WO2008052190A2 (en) * 2006-10-26 2008-05-02 Flynn Gary A Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
CAS RN 1114594-25-0 DATABASE REGISTRY [ONLINE]CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 3 MARCH 2009 (2009-03-03), 3-[(Methylamino)sulfonyl]-4-[(2-methylpropyl)amino]benzoic acid, 3 MARCH 2009 (2009-03-03 *
CAS RN 2213956-22-8 DATABASE REGISTRY [ONLINE]CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 17 APRIL 2018 (2018-04-17), 3-(Aminosulfonyl)-4-[(1,1-dimethylethyl)amino]benzoic acid, 17 April 2018 (2018-04-17) *
CAS RN 2214997-86-9 DATABASE REGISTRY [ONLINE]CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 18 APRIL 2018 (2018-04-18), 4-(Butylamino)-3-[(cyclopropylamino)sulfonyl]benzoic acid, 18 April 2018 (2018-04-18) *
CAS RN 2216443-20-6 DATABASE REGISTRY [ONLINE]CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 20 APRIL 2018 (2018-04-20), 3-[(Cyclohexylamino)sulfonyl]-4-[(2-methoxyethyl)amino]benzoic acid, 20 April 2018 (2018-04-20) *
CAS RN 2216443-43-3 DATABASE REGISTRY [ONLINE]CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 20 APRIL 2018 (2018-04-20), 4-[(2-Methoxyethyl)amino]-3-[(phenylamino)sulfonyl]benzoic acid, 20 April 2018 (2018-04-20) *
CAS RN 2216491-80-2 DATABASE REGISTRY [ONLINE]CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 20 APRIL 2018 (2018-04-20), 4-[(2-Methoxyethyl)amino]-3-[[(3-methoxypropyl)amino]sulfonyl]benzoic acid, 20 April 2018 (2018-04-20) *
CAS RN 697216-84-5 DATABASE REGISTRY [ONLINE]CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 21 JUNE 2004 (2004-06-21), 3-[(Methylamino)sulfonyl]-4-(4-methyl-1-piperazinyl)benzoic acid, 21 JUNE 2004 (2004-06-21) *
CAS RN 737704-11-9 DATABASE REGISTRY [ONLINE]CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2 SEPTEMBER 2004 (2004-09-02), 3-[(Dimethylamino)sulfonyl]-4-(4-ethyl-1-piperazinyl)benzoic acid, 2 SEPTEMBER 2004 (2004-09-02) *
CAS RN 767573-50-2 DATABASE REGISTRY [ONLINE]CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 22 OCTOBER 2004 (2004-10-22), 3-[(Dimethylamino)sulfonyl]-4-(4-methyl-1-piperazinyl)benzoic acid, 22 OCTOBER 2004 (2004-10-22) *
D'AMBROSIO KATIA ET AL, JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, no. 11, 2008, pages 3230 - 3237 *
JENNIFER D. PENSCHOW ET AL, vol. 25, no. S1, 1 November 1998 (1998-11-01), AU, pages S86 - S90 *
PETER W. FEIT ET AL: "Aminobenzoic acid diuretics. 3. 4-Substituted 5-sulfamylanthranilic acid derivatives", JOURNAL OF MEDICINAL CHEMISTRY, vol. 15, no. 1, 1 January 1972 (1972-01-01), pages 79 - 83 *
PIERRE FRANCOTTE ET AL, JOURNAL OF MEDICINAL CHEMISTRY, vol. 53, no. 4, 25 February 2010 (2010-02-25), pages 1700 - 1711 *

Also Published As

Publication number Publication date
CA3135339A1 (en) 2020-10-08
JP7676317B2 (ja) 2025-05-14
US20220184008A1 (en) 2022-06-16
CN120661491A (zh) 2025-09-19
BR112021019935A2 (pt) 2022-03-03
CN114174259A (zh) 2022-03-11
JP2022528271A (ja) 2022-06-09
SG11202110950XA (en) 2021-10-28
WO2020202072A1 (en) 2020-10-08
EP3947345A1 (en) 2022-02-09
KR20220022051A (ko) 2022-02-23
IL286900A (en) 2021-10-31
AU2020251023A1 (en) 2021-11-04
IL286900B2 (en) 2025-03-01
IL286900B1 (en) 2024-11-01

Similar Documents

Publication Publication Date Title
EP2968330B1 (en) Compounds and methods for inducing chondrogenesis
DE60107435T2 (de) 2-adamantylethylamine und deren verwendung bei der behandlung von abnormalitäten in der glutamat transmission
JP6145109B2 (ja) 新規のベンズアミド誘導体、及びこの用途
US10227349B2 (en) Pyrazolo[1,5-a]pyrimidine compound
BR112020020464A2 (pt) Derivados de bumetanida para a terapia da hiperidrose
AU2020251023B2 (en) Modulators of intracellular chloride concentration
CN104926733A (zh) 作为RORγ调节剂的化合物
EP3334727B1 (en) Pyridine and pyrimidine derivatives
BR112019018843A2 (pt) composto, processo para preparar compostos, composição farmacêutica, combinação, processo para fabricação de uma composição farmacêutica, e, método de tratamento e/ou prevenção de um distúrbio
JP4950157B2 (ja) Ｔ型カルシウムチャンネルに活性を有した新規イソインドリノン誘導体及びその製造方法
JPH05186432A (ja) イミダゾール化合物、その製造方法及びその使用方法
CN107531642B (zh) 咪唑衍生物
EP2300424B1 (fr) Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson
WO2019193161A1 (en) Bumetanide derivatives for the therapy of stroke and other neurological diseases/disorders involving nkccs
KR20220004111A (ko) 신장질환의 치료를 위한 신규 화합물 및 그의 약학 조성물
CN108137566B (zh) 三唑衍生物
RU2852940C2 (ru) Модуляторы внутриклеточной концентрации хлоридов
BR112021019935B1 (pt) Composto, uso do composto e composição farmacêutica
TW202604490A (zh) Ｍａｓ相關ｇ蛋白受體ｘ４調節劑及用途
WO2019088057A1 (ja) アニリド誘導体及びその医薬用途
WO2025228419A1 (zh) Mas相关g蛋白受体x4调节剂及用途
FR2955108A1 (fr) Utilisation de derives de pyrrolopyridine comme activateurs de nurr-1, pour le traitement de la maladie de parkinson
HK1099244A1 (en) Tetrahydroindolone derivatives for treatment of neurological conditions
HK1099244B (en) Tetrahydroindolone derivatives for treatment of neurological conditions

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)